Get the Stockscreener App
13.16
1.35%
-0.18
Pre-market:
13.63
0.47
+3.57%
Oric Pharmaceuticals Inc stock is traded at $13.16, with a volume of 1.17M.
It is down -1.35% in the last 24 hours and up +9.67% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$13.34
Open:
$13.24
24h Volume:
1.17M
Relative Volume:
0.98
Market Cap:
$1.28B
Revenue:
-
Net Income/Loss:
$-137.25M
P/E Ratio:
-6.963
EPS:
-1.89
Net Cash Flow:
$-121.97M
1W Performance:
+0.46%
1M Performance:
+9.67%
6M Performance:
+130.47%
1Y Performance:
+40.30%
1-Day Range:
$13.03
$13.57
1-Week Range:
$12.75
$13.81
52-Week Range:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
13.16 | 1.30B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Why ORIC Pharmaceuticals Inc. (4TZ) stock benefits from AI revolutionRisk Management & Technical Pattern Alert System - newser.com
Will ORIC Pharmaceuticals Inc. stock maintain momentum in 2025IPO Watch & Long-Term Investment Growth Plans - newser.com
Sector ETF performance correlation with ORIC Pharmaceuticals Inc.Trade Ideas & Verified Chart Pattern Trade Signals - newser.com
AlphaQuest LLC Lowers Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Multi factor analysis applied to ORIC Pharmaceuticals Inc.Portfolio Risk Summary & AI Powered Market Trend Analysis - newser.com
What to expect from ORIC Pharmaceuticals Inc. in the next 30 daysWeekly Volume Report & Daily Profit Focused Screening - newser.com
Is ORIC Pharmaceuticals Inc. stock attractive after correctionJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Is this a good reentry point in ORIC Pharmaceuticals Inc.Market Volume Summary & AI Driven Stock Movement Reports - newser.com
Published on: 2025-11-02 03:17:27 - newser.com
Why ORIC Pharmaceuticals Inc. (4TZ) stock stays on top picksJuly 2025 Action & High Accuracy Swing Entry Alerts - newser.com
Relative strength of ORIC Pharmaceuticals Inc. in sector analysisJuly 2025 Drop Watch & Long-Term Safe Return Strategies - newser.com
ORIC Pharmaceuticals Inc. stock chart pattern explained2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
How to read the order book for ORIC Pharmaceuticals Inc.2025 Earnings Surprises & Verified Technical Trade Signals - newser.com
D pipelineBull Run & Technical Confirmation Trade Alerts - newser.com
Has ORIC Pharmaceuticals Inc. found a price floorEarnings Miss & Verified Trade Idea Suggestions - newser.com
Sentiment analysis tools applied to ORIC Pharmaceuticals Inc.Market Performance Recap & Daily Technical Stock Forecast Reports - newser.com
What technical models suggest about ORIC Pharmaceuticals Inc.’s comebackDividend Hike & AI Forecast for Swing Trade Picks - newser.com
Will ORIC Pharmaceuticals Inc. stock split again soonJuly 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
Can you recover from losses in ORIC Pharmaceuticals Inc.Quarterly Market Review & Stepwise Trade Execution Plans - newser.com
Wedbush Reiterates "Outperform" Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Oct 06 '25 |
Sale |
14.52 |
11,000 |
159,719 |
48,317 |
| Chacko Jacob | PRESIDENT AND CEO |
Oct 06 '25 |
Sale |
12.32 |
37,461 |
461,520 |
531,419 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):